Novo Nordisk A/S: New data show once-weekly insulin icodec met additional endpoints in adults with type 2 diabetes in phase 3a trials

After achieving primary endpoint by demonstrating superiority and non-inferiority in HbA1C reduction from baseline at week 52, investigative insulin icodec helped patients achieve significantly more time in target blood glucose range (Time in Range) vs once-daily basal insulin glargine U100 in ONWARDS 11In the ONWARDS 1 and 3 trials, more people achieved blood glucose targets without clinically significant or severe hypoglycaemia with once-weekly basal insulin icodec vs once-daily basal insulin

Related Keywords

Canada ,Switzerland ,United States ,San Diego ,California ,Denmark ,China ,Begtrup ,Midtjylland ,Australia ,Brazil ,American , ,Youtube ,Scientific Sessions Of The American Diabetes Association ,Facebook ,Linkedin ,Twitter ,American Diabetes Association ,Novo Nordisk ,Annual Scientific Sessions ,Once Weekly Insulin Icodec ,Glycemic Control ,Daily Insulin Degludec ,Continuous Glucose Monitoring Data Interpretation ,Recommendations From ,International Consensus ,Dosing Guide App ,Basal Insulin Analogs ,Diabetes Association ,Scientific Sessions ,Research Study ,Compare Two Types ,New Insulin ,Insulin Icodec ,Available Insulin ,Insulin Glargine ,People With Type ,Who Have Not Used Insulin Before ,Insulin Degludec ,